🔒
Price chart and 15 days of daily prices
Candlestick chart with moving averages, Bollinger bands and MACD.
Register free to view.
Security Profile
- Security Type
- Common Stock
- CUSIP
- 00972G108 (prev. 15119A103 )
- Market Cap
- Micro Cap
- IPO
- 1/31/2014 · $6.00/share
- ADR Ratio
- 1:100
- Previous Symbol
- CLTX (changed 9/21/2015)
- Previous Name
- Celsus Therapeutics Plc
Business: Akari Therapeutics, Plc iis a biopharmaceutical company focused on developing inhibitors of acute and chronic inflammation, specifically for the treatment of rare and orphan diseases, in particular those where the complement (C5) or leukotriene (LTB4) systems, or both complement and leukotrienes together, play a primary role in disease progression.
Notes: September 18, 2015 -- Celsus Therapeutics Plc (NASDAQ: CLTX) and Volution Immuno Pharmaceuticals SA today announced that, following shareholder approval obtained at a general meeting of the shareholders of Celsus held on September 16, 2015, the previously announced acquisition by Celsus of Volution has closed. The combined company has changed its name to Akari Therapeutics, Plc and will trade on the NASDAQ Capital Market under the symbol AKTX beginning on September 21, 2015.
Company Contact
- CEO
- Abizer Gaslightwala
- CFO
- Kameel D. Farag
- Headquarters
- 401 East Jackson Street, Suite 3300, Tampa, FL 33602
- Phone
- 929-274-7510
- Fax
- 646-843-9352
- Investor Relations
- Jenene Thomas, JTC Team · 908-824-0775 · AKTX@jtcir.com